Literature DB >> 12441039

Assessing disease activity and disease activity indices for inflammatory bowel disease.

Feng Xiao Li1, Lloyd R Sutherland.   

Abstract

A crucial step in the development of clinical trials to determine the efficacy of various therapies for inflammatory bowel disease (IBD) has been the creation of activity indices. This article reviews the major components and operating characteristics of clinical activity indices commonly used in randomized, controlled trials of IBD therapy. In addition, the paper provides a brief overview of the developmental requirements for any new index.

Entities:  

Mesh：

Year:  2002        PMID： 12441039     DOI： 10.1007/s11894-002-0025-z

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


  44 in total

1.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

Authors:  B G Feagan; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; J Koval; C J Wong; M Hopkins; S B Hanauer; J W McDonald
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

2.  Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).

Authors:  C Florent; A Cortot; P Quandale; T Sahmound; R Modigliani; E Sarfaty; P Valleur; J L Dupas; M Daurat; J L Faucheron; E Lerebours; F Michot; J Belaiche; N Jacquet; J C Soulé; N Rothman; J P Gendre; M Malafosse
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-03       Impact factor: 2.566

3.  Reproducibility of colonoscopic findings in Crohn's disease: a prospective multicenter study of interobserver variation. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors: 
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

4.  Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis.

Authors:  J Powell-Tuck; D W Day; N A Buckell; J Wadsworth; J E Lennard-Jones
Journal:  Dig Dis Sci       Date:  1982-06       Impact factor: 3.199

5.  National Cooperative Crohn's Disease Study: study design and conduct of the study.

Authors:  D H Winship; R W Summers; J W Singleton; W R Best; J M Becktel; L F Lenk; F Kern
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

6.  Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.

Authors:  B Landi; T N Anh; A Cortot; J C Soule; E Rene; J P Gendre; P Bories; A See; E H Metman; C Florent
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

7.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

8.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

9.  Comparison of beclomethasone dipropionate (2 and 3 mg) and prednisolone sodium phosphate enemas (30 mg) in the treatment of ulcerative proctitis. An adrenocortical approach.

Authors:  C J Mulder; E Endert; H van der Heide; H J Houthoff; W Wiersinga; E H Wiltink; G N Tytgat
Journal:  Neth J Med       Date:  1989-08       Impact factor: 1.422

10.  Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group.

Authors:  E J Irvine
Journal:  J Clin Gastroenterol       Date:  1995-01       Impact factor: 3.062
View more
  4 in total

Review 1.  AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Siddharth Singh; Joseph D Feuerstein; David G Binion; William J Tremaine
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

2.  Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease.

Authors:  Magali Fasseu; Xavier Tréton; Cécile Guichard; Eric Pedruzzi; Dominique Cazals-Hatem; Christophe Richard; Thomas Aparicio; Fanny Daniel; Jean-Claude Soulé; Richard Moreau; Yoram Bouhnik; Marc Laburthe; André Groyer; Eric Ogier-Denis
Journal:  PLoS One       Date:  2010-10-05       Impact factor: 3.240

3.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study.

Authors:  Roopali Bansal Gupta; Noam Harpaz; Steven Itzkowitz; Sabera Hossain; Sierra Matula; Asher Kornbluth; Carol Bodian; Thomas Ullman
Journal:  Gastroenterology       Date:  2007-08-02       Impact factor: 22.682

4.  CD4+ CD25+ FOXP3+ T cell frequency in the peripheral blood is a biomarker that distinguishes intestinal tuberculosis from Crohn's disease.

Authors:  Veena Tiwari; Saurabh Kedia; Sushil Kumar Garg; Ritika Rampal; V Pratap Mouli; Anuja Purwar; D K Mitra; Prasenjit Das; S Dattagupta; Govind Makharia; S K Acharya; Vineet Ahuja
Journal:  PLoS One       Date:  2018-02-28       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.